Heron Therapeutics (NASDAQ:HRTX) Stock Price Up 5%

Heron Therapeutics, Inc. (NASDAQ:HRTX) was up 5% during mid-day trading on Tuesday . The company traded as high as $3.38 and last traded at $3.38. Approximately 121,465 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 2,614,209 shares. The stock had previously closed at $3.22.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HRTX shares. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Thursday, May 16th. Capital One Financial started coverage on Heron Therapeutics in a research report on Tuesday, April 23rd. They set an “overweight” rating and a $6.00 price target for the company. Finally, Rodman & Renshaw assumed coverage on Heron Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Heron Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $6.00.

Heron Therapeutics Stock Up 8.7 %

The stock’s 50 day moving average price is $3.09 and its two-hundred day moving average price is $2.59. The stock has a market cap of $528.78 million, a price-to-earnings ratio of -5.59 and a beta of 1.81.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.06. The business had revenue of $34.67 million during the quarter, compared to analysts’ expectations of $32.50 million. On average, analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. grew its stake in shares of Heron Therapeutics by 100.0% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,060,000 after purchasing an additional 1,000,000 shares during the period. Congress Park Capital LLC increased its holdings in Heron Therapeutics by 205.3% in the fourth quarter. Congress Park Capital LLC now owns 1,798,650 shares of the biotechnology company’s stock valued at $3,058,000 after buying an additional 1,209,500 shares in the last quarter. Monaco Asset Management SAM raised its position in shares of Heron Therapeutics by 219.5% in the fourth quarter. Monaco Asset Management SAM now owns 2,226,475 shares of the biotechnology company’s stock worth $3,785,000 after acquiring an additional 1,529,567 shares during the period. Los Angeles Capital Management LLC raised its position in shares of Heron Therapeutics by 49.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 514,377 shares of the biotechnology company’s stock worth $874,000 after acquiring an additional 171,250 shares during the period. Finally, Orchard Capital Management LLC boosted its stake in shares of Heron Therapeutics by 4.7% during the 4th quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after acquiring an additional 100,603 shares in the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.